Methadone Use and the Risk of Hypoglycemia for Inpatients With Cancer Pain

Accepted Manuscript Methadone Use and the Risk of Hypoglycemia for Inpatients with Cancer Pain James H. Flory, MD, MSCE, Alison C. Wiesenthal, MD, Howard T. Thaler, PhD, Lauren Koranteng, PharmD, Natalie Moryl, MD PII:

S0885-3924(15)00447-9

DOI:

10.1016/j.jpainsymman.2015.08.003

Reference:

JPS 8964

To appear in:

Journal of Pain and Symptom Management

Received Date: 26 May 2015 Revised Date:

11 August 2015

Accepted Date: 16 August 2015

Please cite this article as: Flory JH, Wiesenthal AC, Thaler HT, Koranteng L, Moryl N, Methadone Use and the Risk of Hypoglycemia for Inpatients with Cancer Pain, Journal of Pain and Symptom Management (2015), doi: 10.1016/j.jpainsymman.2015.08.003. This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

Original Article

15-00341R1

Methadone Use and the Risk of Hypoglycemia for Inpatients with Cancer Pain

Koranteng, PharmD, and Natalie Moryl, MD

RI PT

James H. Flory, MD, MSCE, Alison C. Wiesenthal, MD, Howard T. Thaler, PhD, Lauren

SC

Division of Endocrinology (J.H.F.), Weill Cornell Medical College; and Palliative Medicine Service (A.C.W., L.K., N.M.), Department of Medicine, and Department of Epidemiology and

Address correspondence to: James H. Flory, MD, MSCE

TE D

1300 York Avenue

M AN U

Biostatistics (H.T.T.), Memorial Sloan Kettering Cancer Center, New York, New York, USA

New York, NY 10065, USA

AC C

EP

E-mail: [email protected]

1

ACCEPTED MANUSCRIPT

Abstract Context. Methadone is an important drug in the management of both cancer-related and non-cancer-related pain and is the main pharmacologic agent used in the treatment of opioid

RI PT

addiction. Unexpected hypoglycemia has been observed in patients receiving methadone, prompting a more detailed investigation.

Objectives. To evaluate the incidence of hypoglycemia in a cohort of inpatients receiving

SC

methadone versus other opioids including fentanyl, hydromorphone and morphine.

Methods. Retrospective observational cohort of inpatients in a tertiary cancer center

M AN U

admitted for more than 48 hours from November 1, 2011 to October 30, 2013. The main outcomes were lowest measured daily blood glucose (in mg/dl) and incidence of hypoglycemia (defined as blood glucose < 70 mg/dl, equivalent to 3.9 mmol/l) with variable methadone doses compared with other non-methadone opioids.

TE D

Results. Of the 641 eligible patients admitted during the study period who received at least one dose of methadone during admission, multivariable logistic regression showed significant associations between methadone and hypoglycemia at doses greater than 40 mg oral

EP

equivalents per day or with patient-controlled analgesia (PCA) use. A dose-response relationship was observed, with an odds ratio of 3.1 (95% confidence interval 2.5, 3.6) when

AC C

doses greater than 80 mg/day were used. No evidence of increased risk of hypoglycemia or of a dose-response curve was seen for the other opioids. Conclusion. The risk of hypoglycemia is increased for patients taking more than 40 mg

oral methadone equivalents per day. When starting methadone at or above 40 mg a day, we recommend routine blood glucose monitoring.

2

ACCEPTED MANUSCRIPT

Key Words: methadone, hypoglycemia Running Title: Methadone Use and the Risk of Hypoglycemia

RI PT

Accepted for publication: August 21, 2015.

AC C

EP

TE D

M AN U

SC

AU: PLEASE CLARIFY WHETHER ALL INSTANCES OF PATIENT-DAYS SHOULD BE CHANGED TO PERSON-DAYS THROUGHOUT

3

ACCEPTED MANUSCRIPT

Introduction Methadone, an opioid agonist, can be an effective medication for severe pain when administered by experienced prescribers. For patients with liver and renal impairment, severe

RI PT

neuropathic pain or pain refractory to other opioids, methadone may be the preferred opioids.1 Its use in the United States has increased in the past decade, with approximately 4.4 million

prescriptions written annually.2 Methadone is the main pharmacological intervention in the

SC

treatment of opioid dependence.3 Potential advantages over other opioids include low cost, high bioavailability, long half-life and lack of active metabolites. Methadone also interacts with the

M AN U

N-methyl-D-aspartate (NMDA) receptor, which is thought to mediate peripheral sensitization and visceral pain.4 Safety, however, has been a recurring theme in the expansion of methadone use, with problems related both to overdose and QT-prolongation with high doses.5,6,7,8 Methadone shares a similar side-effect profile with other opioids including morphine,

TE D

hydromorphone and fentanyl, with serious reactions that include respiratory depression, apnea, and risk of dependency and common reactions including dizziness, sedation, nausea/vomiting and constipation. Uniquely, methadone has been shown to increase QTC in selected cases, and

screening.9

EP

dosing of the medication at over 100 milligrams per day warrants periodic electrocardiogram

AC C

Previous literature has suggested an association between methadone and hypoglycemia,

although no human studies have compared the effect of methadone versus other opioids on blood glucose. A case report and subsequent case series by Moryl et al. showed hypoglycemia in 19% of 59 patients during rapid escalation of methadone dose in the inpatient setting.10 Follow-up research in a mouse model showed that intravenous methadone lowered blood glucose in a dosedependent manner, with only doses greater than 10 mg/kg significantly lowering blood glucose

4

ACCEPTED MANUSCRIPT

levels.11 Other opioids in that preclinical study included morphine, fentanyl, and oxycodone, none of which affected blood glucose levels. A similar effect has been described in the literature with tramadol and dextropropoxyphene.12, 13, 14, 15,16 The evidence to date raises a potentially

RI PT

serious safety concern, as even mild hypoglycemia can significantly impact patients’ quality of life, and severe hypoglycemia can lead to morbidity and death through mechanisms ranging from neurological damage to cardiac arrhythmias.17, 18

SC

We undertook a retrospective cohort study in order to test the hypothesis that methadone causes hypoglycemia in humans, quantify such risk and its relation to measured confounders,

M AN U

and assess for a dose-response effect. We designed the present study to evaluate the incidence of hypoglycemia in a cohort of inpatients receiving methadone versus other commonly prescribed opioids. Methods

TE D

Design

This was a retrospective cohort study designed to test the a priori hypothesis that methadone administration is acutely associated with lowering of blood glucose and episodes of

EP

hypoglycemia defined as blood glucose < 70 mg/dl, equivalent to 3.9 mmol/l. The cohort comprised patients 18 years of age or older admitted for more than 48 hours at a tertiary cancer

AC C

center between November 1, 2011 and October 30, 2013 who received at least one dose of methadone during their inpatient stay. No further exclusion criteria were applied. The study was designed as a retrospective cohort with repeated measures of glucose

levels over time, hierarchical at the patient level. The primary unit of analysis was person-days, with analysis focused on changes in blood glucose and risk of hypoglycemia over time. Patients receiving methadone commonly received other opioids during the same admission, before,

5

ACCEPTED MANUSCRIPT

during, and after methadone exposure. These exposures to other opioids were treated as covariates and included in the analysis. The major advantage of this design was to allow patients to serve as their own controls, reducing the effect of non-time-varying confounders. 19 This

RI PT

approach was chosen over a more conventional propensity-score matching design (in which users of methadone would have been matched to other patients with no methadone exposure) because methadone may be used in refractory pain for patients who have failed other opioids and

SC

may intrinsically be “sicker,” with higher baseline risk for hypoglycemia because of advanced disease, poor oral intake, and other factors than matched controls.

M AN U

In a secondary analysis, separate cohorts of patients who were admitted and treated with monotherapy of hydromorphone, morphine, or fentanyl were examined for evidence of hypoglycemic effect. Patients were only eligible for this cohort if they received at least one dose of the opioid of interest and no doses of any other opioid. Inclusion criteria were otherwise

Data Collection

TE D

identical to the primary cohort.

Exposure to methadone was defined based on electronic health records (EHR) of opioid

EP

administration and it included oral (PO), intravenous (IV) and IV delivered via patient-controlled analgesia (PCA). As conversion ratios from methadone to other opioids vary greatly, we

AC C

converted morphine, hydromorphone, and fentanyl to methadone based on the well-established opioid ratios recommended by the National Comprehensive Cancer Network.20 All opioids are reported as their equivalent in mg of oral methadone throughout the manuscript.21 Opioid doses were divided into quartiles corresponding to the observed doses of daily oral methadone in this population so that dose categories were directly comparable across classes. Each person-day when the patient was on or off methadone was included in the study, so single patients may be

6

ACCEPTED MANUSCRIPT

included in multiple categories. In the primary analysis, all non-methadone opioids were analyzed as a single group. In the secondary analysis, each opioid was treated as a distinct exposure category.

RI PT

Exposure to PCA was represented as a dichotomous variable as total dose administered through PCA was not recorded in the EHR. Clinician administered boluses via PCA were

captured in the EHR and quantified as normal IV exposure; in such cases, patients would be

SC

classified as exposed to both a known clinician-administered IV dose and the unquantified basal and patient-administered opioid.

M AN U

Outcomes

The study has two primary outcomes: lowest recorded blood glucose on a given day, and presence or absence of hypoglycemia on a given day.22 On days where glucose was not measured, hypoglycemia was assumed not to occur. In sensitivity analysis, the cohort was

TE D

restricted to patients with glucose measured on over 90% of days. The values were extracted from the EHR and included both glucose reported on serum chemistry analyses and those measured by finger stick. Methadone and other opioid exposures on a given day (t) were

EP

assumed to affect blood glucose on the next day (t+1). Statistical Analysis

AC C

Baseline covariates were: sex, age, body mass index (BMI) calculated as kg/m2,

estimated glomerular filtration rate (eGFR) calculated using a Modification of Diet in Renal Disease study equation, serum albumin and admitting service. 23 Time-varying covariates were dose and route of administration of other opioids, and factors affecting blood glucose including nil per os (NPO) status, use of antidiabetic drugs, and use of steroids. In the primary

7

ACCEPTED MANUSCRIPT

multivariable analysis the three other commonly used opioids (morphine, hydromorphone, and fentanyl) were combined into one exposure category (non-methadone). Initial descriptive analysis using admission and person-days as the units of analysis was

RI PT

conducted. For adjusted estimates of the effect of methadone exposure on lowest blood glucose, mixed linear modeling, hierarchical at the level of admission, was used. For adjusted estimates of methadone’s effect on risk of hypoglycemia, a mixed logistic modeling, hierarchical at the level

SC

of admission, was used. For both models, for each admission, sex, age, BMI, renal function, type of admission (surgical, medical, or other) and serum albumin were forced into the model as

M AN U

baseline covariates. In addition, dose of non-methadone opioids, exposure to steroids, and exposure to hypoglycemic drugs were forced into the model as time-varying covariates. Additional post-hoc analysis was undertaken using random slopes models to examine how the risk of hypoglycemia changed over time before, during, and after methadone exposure. R v. 3.0.1

Austria).

TE D

was used for all analyses, with the Hmisc and lme4 libraries (The R foundation, Vienna,

This retrospective study was reviewed and approved by the Memorial Sloan Kettering

Results

EP

Cancer Center Institutional Review Board.

AC C

During the two-year study period, 641 unique patients were admitted who met the study

criteria of admission greater than 48 hours and who received at least one dose of methadone during admission, with a total of 1085 eligible admissions and 11,980 person-days. Of admissions, 47.0% were female; 21.7% were older than 65 years, 85.9% had a BMI greater than 20 on admission, and 86.9% had an eGFR of greater than 60 ml/min.

8

ACCEPTED MANUSCRIPT

Of the patients with methadone exposure (7682 patient days [64%]), a majority (86.3%) also received opioids other than methadone. The interquartile range of oral methadone equivalent dosing was 15 to 80 mg/day. For over half of admissions (51.2%), glucose was

RI PT

measured on over 90% of days (Table 1).

Methadone PCA was used on 4.5% of patient days. Other opioids were administered by both PO and non-PCA IV routes. Non-methadone PCA was used on 42.2% of patient-days; 5.2%

SC

of patient-days were exposed to diabetes drugs, and 9.9% of person-days had documented NPO status. Also, 38.8% of patient days involved steroid exposure (Table 2).

M AN U

Of days without methadone exposure, 188 person-days had hypoglycemia (3.7%). Of days with methadone exposure, there were 532 patient-days (6.9%) with hypoglycemia. Of these events occurring while on methadone, 35% was to a glucose < 60 mg/dl (3.3 mmol/l), 10% was to a glucose < 50 mg/dl (2.8 mmol/l), and 3% was to a glucose < 40 mg/dl (2.2 mmol/l).

TE D

Logistic multivariable regression showed a significant association between methadone and hypoglycemia, with an odds ratio (OR) of 2.2 (95% confidence interval [CI] 1.6, 2.9). An approximately linear association between hypoglycemia and methadone dose was present, with

EP

ORs of 2.9-3.1 at the highest dosing quartile and an OR of 2.9 (95% CI 1.8, 4.6) when a PCA was used. No evidence of increased risk of hypoglycemia or of a dose-response curve was seen

AC C

with these same patients while exposed to the other opioids, including at daily doses exceeding the equivalent of 80 mg/day of oral methadone (Fig. 1). Linear multivariable regression showed methadone to be significantly associated with

reduced average minimum daily blood sugar by -5.7 mg/dl (95% CI -7.3, -4.1, equivalent to mmol/l 0.31), with increasing doses associated with greater negative effect (Fig. 2).

9

ACCEPTED MANUSCRIPT

On secondary analysis, three separate cohorts were identified consisting of patients admitted and exposed to only one opioid: morphine (3557 admissions with 10,347 exposed patient-days), hydromorphone (4076 with 11,639 exposed patient-days), or fentanyl (8199

RI PT

admissions with 2748 exposed patient-days). Consistent with the primary analysis, no

association between opioid exposure and either decreased blood glucose or increased incidence of hypoglycemia was seen in any of these cohorts.

SC

Glucose data were missing on 16.8% of patient-days overall, although 43.9% of the

cohort had no missing blood glucose values. An additional 52% of patient-days had a single

M AN U

blood glucose measured, and the remainder had multiple measurements per day. Blood glucose in the overall cohort was missing more often on days when methadone was being administered, with an OR of missing data of 1.04 (95% CI 1.03, 1.06), while other opioids were not associated with more missing data. On sensitivity analysis, the cohort was restricted to admissions on which

TE D

glucose was measured on 100% of patient days, and results were not materially affected (Supplementary Data, available at jpsmjournal.com). Of note, this restriction eliminated any association between rate of missingness and methadone exposure.

EP

Additional sensitivity analyses were undertaken. The assumption that opioids given on one day would affect glucose levels the next day was varied, from modeling that assumed the

AC C

effect would be seen on the same day as opioid administration to models that assumed the effect would be seen two days later. In additional sensitivity analysis, other opioids were treated as distinct exposure categories. Results were not materially altered in any of these analyses, except that assuming the effect of methadone would be seen on days other than t+1 attenuated the strength of the association.

10

ACCEPTED MANUSCRIPT

On post-hoc analysis, the cohort was restricted to patients who were admitted for at least 24 hours with no methadone administration and then started on methadone. The association of methadone with reduced serum blood glucose was time-dependent and progressive when the

RI PT

dose of methadone exceeded 40 mg oral equivalents per day (P <0.01, linear test for trend) (Fig. 3, left upper panel). For methadone doses below 40 mg oral equivalents per day, no such

relationship was present (Fig. 3, left lower panel). The increased risk of hypoglycemia was seen

SC

within 24 hours of methadone use at higher doses (P < 0.01) (Fig. 3, right upper panel). Patients who experienced hypoglycemia on methadone were at elevated risk for additional episodes while

M AN U

on methadone; an episode of hypoglycemia conferred an OR of 4.0 (95% CI 2.3, 7.0) for hypoglycemia the next day. Discussion

This retrospective study found a strong association between methadone exposure and

TE D

reduction in blood glucose and a significantly increased rate of hypoglycemia. For any methadone exposure, the per-day rate of hypoglycemia was 6.9%. The effect appears to be comparable for both IV and PO administration of methadone (Table 3). These risks exceed those

EP

commonly seen with patients receiving insulin in the inpatient setting (approximately 3.2% per day).24 A clear dose-response curve is evident, and is robust to multivariable adjustment. The

AC C

association is time-dependent, occurring approximately 24 hours after initiation of methadone. Similar effects are not seen for other opioids in the same cohort of patients, suggesting that this effect may be specific to methadone. These findings support the a priori hypothesis that methadone can cause hypoglycemia

and shows a clinically relevant increase in rates of hypoglycemia, particularly at doses greater than 40 mg orally daily and with methadone PCA. While observational, these data suggest that

11

ACCEPTED MANUSCRIPT

serum glucose should be monitored in patients taking higher doses of methadone, and methadone use should be included in the differential diagnosis for unexplained hypoglycemia. Opioids have previously been noted to affect endocrine systems in a wide variety of

RI PT

ways, including modulation of pancreatic exocrine secretion and suppression of the

hypothalamic-pituitary-adrenal (HPA) axis. 25,26,27 Methadone’s uniquely variable and relatively long half-life in comparison to other opioids may suggest a mechanism related to its constant

SC

effect on the HPA axis. Methadone displays antagonistic activity at the NMDA receptor and inhibits the reuptake of serotonin and norepinephrine in the central nervous system. 28,29 Possible

M AN U

etiologies of hypoglycemia may include suppression of counter-regulatory mechanisms or promotion of pancreatic insulin release, although additional investigation is required. Other more general possibilities include suppression of counter-regulatory mechanisms such as glucagon, epinephrine and sympathoadrenal responses to hypoglycemia.

TE D

This study has limitations. As an observational study based on data automatically extracted from a large number of EHR, we did not have access to all relevant covariates, such as functional status. The outcomes are based on glucose as measured in routine clinical care, which

EP

means that glucose was measured at a variety of times, with a variety of methods (both bedside glucometers and serum glucose measurements), without a record of whether samples represent

AC C

fasting or non-fasting glucose. All of these sources of variation could potentially introduce bias. Also, glucose was not measured on all patient days, creating a potential for ascertainment bias in the primary analysis. The pattern of missing data was non-random; glucose was less often measured when methadone was used, which would bias the analysis against showing an increased risk of hypoglycemia with methadone. This suggests that the risk of hypoglycemia

12

ACCEPTED MANUSCRIPT

from methadone may be greater than reported here. Results were robust to sensitivity analysis, including restriction to admissions with no missing data. An additional limitation introduced by the random nature of the glucose measurements

RI PT

and the complex real-world dosing regimens observed is that it was difficult to assess how the effect of exposure to a single dose of methadone evolved over time. The crude assumption that effects of methadone on blood sugar on a given day would be most strongly seen the next day is

SC

a limitation of this study that would be best addressed by prospective research.

In addition, while the design minimizes problems with baseline confounders, it is still

M AN U

vulnerable to problems with time-varying confounding. If methadone, particularly at high doses, tends be used in clinical scenarios where hypoglycemia is particularly likely, the pattern of results found here could occur in the absence of a true pharmacologic effect. The fact that these results are robust to multivariable adjustment and are not seen even at high doses of other opioids

TE D

is reassuring. Finally, the retrospective design of the study does not provide evidence that the hypoglycemic events were clinically significant. However, a third of the incidents of hypoglycemia associated with methadone exposure were to a glucose of < 60 mg/dl (3.3

EP

mmol/l), and 10% were to a glucose < 50 mg/dl (2.8 mmol/l), levels at which both autonomic nervous system activation and impairment of cognitive function are typically seen. 30

AC C

In conclusion, this observational study raises a significant and easily remedied safety

concern about the use of methadone. Clinicians who prescribe methadone should be wellinformed of the risk and symptoms of hypoglycemia and monitor their patients appropriately. Particularly when higher doses of methadone are used, periodic blood glucose checks may be prudent, and methadone use should be considered on the differential for unexplained hypoglycemia. Further research is warranted to verify these findings using randomized data,

13

ACCEPTED MANUSCRIPT

exploration of their implications in the outpatient setting and elucidation of possible mechanisms. Disclosures and Acknowledgments

AC C

EP

TE D

M AN U

SC

RI PT

No funding was received for this study and the authors report no conflicts of interest.

14

ACCEPTED MANUSCRIPT

641

Number of Admissions

1085

Patient-Days

11980 Number of Admissions

(%)

SC

Patients

RI PT

N

Male

575

53.0%

Female

510

Age < 40

242

22.3%

Age 40-65

608

56.0%

Age > 65

235

21.7%

TE D

M AN U

47.0%

820

75.6%

179

16.5%

54

5.0%

BMI < 20 kg/m2

153

14.1%

BMI 20-25 kg/m2

336

31.0%

BMI 25-30 kg/m2

282

26.0%

BMI > 30 kg/m2

186

17.1%

Medical Admission

AC C

Other Admission

EP

Surgical Admission

15

ACCEPTED MANUSCRIPT

31

2.9%

GFR 30-60 ml/min

101

9.3%

GFR > 60 ml/min

943

86.9%

Albumin < 3 g/dl

1907

15.9%

Albumin >= 3 g/dl

8518

71.1%

Glucose Measured < 50% of Days

115

Glucose Measured 50-99% of Days

494

Glucose Measured 100% of Days

476

43.9%

% Using Methadone

1085

100.0%

% Using Other Opioids

936

86.3%

SC

RI PT

GFR < 30 ml/min

10.6%

TE D

M AN U

45.5%

878

75.0%

93

7.9%

109

9.3%

107

9.1%

96

8.2%

Prostate

76

6.5%

Lung

98

8.4%

Nonovarian Gyn

68

5.8%

Liver

28

2.4%

Hematologic Connective Tissue

Bowel

AC C

Breast

EP

Metastatic Cancer

16

ACCEPTED MANUSCRIPT

58

5.0%

Renal Disease

87

7.4%

Major Liver Disease

15

1.3%

Diabetes

31

2.6%

Cardiovascular Disease

72

6.2%

SC

M AN U

Table 1. Patient characteristics by admission

RI PT

Other

Number of PatientDays

(%)

1033

8.6%

Oral Methadone 15-40 mg

1883

15.7%

Oral Methadone 40-80 mg

1827

15.3%

Oral Methadone > 80 mg

1761

14.7%

IV Methadone 0-15 mg equivalent

314

2.6%

IV Methadone 15-40 mg equivalent

498

4.2%

IV Methadone 40-80 mg equivalent

349

2.9%

IV Methadone > 80 mg equivalent

345

2.9%

PCA Methadone

542

4.5%

AC C

EP

TE D

Oral Methadone 0-15 mg

17

ACCEPTED MANUSCRIPT

1372

11.5%

Oral Non-methadone Opioid 15-40 mg equivalent

130

1.1%

Oral Non-methadone Opioid 40-80 mg equivalent

43

0.4%

Oral Non-methadone Opioid > 80 mg equivalent

71

0.6%

IV Non-methadone Opioid 0-15 mg equivalent

2597

21.7%

791

6.6%

530

4.4%

IV Non-methadone Opioid > 80 mg equivalent

1056

8.8%

PCA Non-methadone Opioid

5060

42.2%

1236

10.3%

628

5.2%

Days With Steroid Exposure

4653

38.8%

Days With NPO Order

1181

9.9%

TE D

Transdermal Fentanyl

M AN U

IV Non-methadone Opioid 40-80 mg equivalent

EP

Days With Diabetes Drug Exposure

AC C

SC

IV Non-methadone Opioid 15-40 mg equivalent

RI PT

Oral Non-methadone Opioid 0-15 mg equivalent

Table 2. Patient days on methadone versus other opioids. All opioid doses are adjusted and reported as their equivalent in oral methadone.

18

ACCEPTED MANUSCRIPT

Methadone % Days With

Exposed Hypoglycemia 95% CI Oral 0-15 mg

Days

% Days With

Exposed

Hypoglycemia 95% CI

1103

3.8

(2.8-5.1)

4.2

(1.4-11.5)

RI PT

Days

Hydromorphone

3.9

(2.9-5.2)

1883

4.2

(3.4-5.2)

equivalent

1827

7.4

(6.3-8.7)

0

Oral > 80 equivalent

1761

8.0

(6.8-9.3)

1

0.0

(0.0-94.9)

IV 0-15 mg equivalent

314

5.7

(3.7-8.9)

1995

5.0

(4.1-6.1)

equivalent Oral 40-80 mg

TE D

IV 15-40 mg equivalent IV 40-80 mg

AC C

IV > 80 mg equivalent

5.6

(3.9-8.0)

562

5.2

(3.6-7.3)

349

12.6

(9.5-16.5)

188

6.4

(3.7-10.8)

13.0

(9.9-17.0)

106

2.8

(1.0-8.0)

2375

4.7

(3.9-5.6)

345

542

(13.516.4

19.8)

Morphine Days

Oral 0-15 mg

72

498

EP

equivalent

PCA

M AN U

Oral 15-40 mg

SC

1033

equivalent

Fentanyl % Days With

Days

% Days With

Exposed Hypoglycemia 95% CI

Exposed

Hypoglycemia 95% CI

297

0

5.1

(3.1-8.2)

19

ACCEPTED MANUSCRIPT

equivalent Oral 15-40 mg 1.8

(0.1-9.4)

equivalent

37

0.0

(0.0-9.4)

Oral > 80 equivalent

43

0.0

(0.0-8.2)

IV 0-15 mg equivalent

710

5.1

(3.7-6.9)

33

18.2

equivalent

2

0.0

IV > 80 mg equivalent

0

PCA

575

Oral 40-80 mg

Transdermal

5.2

TE D

IV 40-80 mg

(0.0-94.9)

0.0

(0.0-39.0)

27

3.7

(0.2-18.3)

102

7.8

(4.0-14.7)

(8.6-34.4)

227

4.8

(2.7-8.5)

(0.0-65.8)

345

2.0

(1.0-4.1)

948

2.8

(2.0-4.1)

2241

3.1

(2.4-3.9)

1236

2.3

(1.6-3.3)

SC

equivalent

0.0

6

M AN U

IV 15-40 mg

1

RI PT

56

equivalent

(3.7-7.4)

EP

Table 3. Event rates in drug exposure categories including methadone, hydromorphone, morphine and fentanyl. All opioid doses are adjusted and reported as their equivalent in oral

AC C

methadone.

20

RI PT

ACCEPTED MANUSCRIPT

Figure Legends

SC

Fig. 1. Adjusted odds ratio for hypoglycemia. * denotes adjusted dose, reported as its equivalent

M AN U

in oral methadone. Reference category is days with no methadone or other opioid exposure.

Fig. 2. Changes in blood glucose with time-varying exposures. * denotes adjusted dose, reported as its equivalent in oral methadone. Reference category is days with no methadone or other

TE D

opioid exposure.

Fig. 3. Time trends with higher dose (> 40 mg/day equivalent dose, or PCA) versus lower dose

AC C

EP

(≤ 40 mg/day equivalent dose) methadone

References

21

ACCEPTED MANUSCRIPT

1

Brown R, Kraus C, Fleming M, Reddy S. Methadone: applied pharmacology and use as

adjunctive treatment in chronic pain. Postgrad Med J 2004;80:654-659. Centers for Disease Control and Prevention (CDC). Vital signs: Risk for overdose from

RI PT

2

methadone used for pain relief – United States, 1999–2010. MMWR Morb Mortal Wkly Rep 2012; 61:493-497.

Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or

SC

3

methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2008;2:

4

M AN U

CD002207.

Petrenko AB, Yamakura T, Baba H, Shimoji K. The role of N-methyl-D-aspartate (NMDA)

receptors in pain: a review. Anesth Analg 2003;97:1108-1116. 5

Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Dose-response effects of methadone in the

treatment of opioid dependence. Ann Intern Med 1993;119:23-27.

Pearson EC, Woosley RL. QT prolongation and torsades de pointes among methadone users:

TE D

6

reports to the FDA spontaneous reporting system. Pharmacoepidemiol Drug Saf 2005;14:747-

7

EP

753.

Maingi S, Moryl N, Faskowitz A. Symptomatic hypoglycemia due to escalating doses of

8

AC C

intravenous methadone. J Pain 2008;9(Suppl 2):37. AU: IS THIS AN ABSTRACT? Ray WA, Chung CP, Murray KT, et al. Out-of-hospital mortality among patients receiving

methadone for noncancer pain. JAMA Intern Med 2015;175:420-427. 9

Chou R, Cruciani RA, Fiellin DA, et al. Methadone safety: a clinical practice guideline from

the American Pain Society and College on Problems of Drug Dependence, in collaboration with the Heart Rhythm Society. J Pain 2014;15:321-337.

22

ACCEPTED MANUSCRIPT

10

Moryl N, Pope J, Obbens E. Hypoglycemia during rapid methadone dose escalation. J Opioid

Manag 2013;9:29-34. Faskowitz AJ, Kramskiy VN, Pasternak GW. Methadone-induced hypoglycemia Cell Mol

RI PT

11

Neurobiol 2013;33:537–542. 12

Abadie D, Durrieu G, Roussin A, Montastruc JL. "Serious" adverse drug reactions with

13

SC

tramadol: a 2010-2011 pharmacovigilance survey in France. Therapie 2013;68:77-84.

Mugunthan N, Davoren P. Danger of hypoglycemia due to acute tramadol poisoning. Endocr

14

M AN U

Pract 2012;18:e151-e152.

Bourne C, Gouraud A, Daveluy A, et al.; French Association of Regional

Pharmacovigilance Centres. Tramadol and hypoglycaemia: comparison with other step 2 analgesic drugs. Br J Clin Pharmacol 2013;75:1063-1067.

Lowenstein W, Fadlallah JP, Haas C, Durand H. Hypoglycemia induced by

TE D

15

dextropropoxyphene: an emergency in drug addicts. [In French]. Presse Medicale. 1993; 22:133. 16

17

EP

Laurent M, Gallinari C, Bonnin M, Soubrie C. Hypoglycemia induced by dextropropoxyphene in very old subjects. 7 cases. [In French]. Presse Medicale 1991;20:1628 Fulcher G, Singer J, Castañeda R, et al. The psychosocial and financial impact of non-severe

11. 18

AC C

hypoglycemic events on people with diabetes: two international surveys. J Med Econ 2014;5:1-

Cryer PE. Mechanisms of hypoglycemia-associated autonomic failure in diabetes. N Engl J

Med 2013;369:362-372. 19

Louis TA, Lavori PW, Bailar JC III, et al. Crossover and self-controlled designs in clinical

research. N Engl J Med 1984;310:24-31.

23

ACCEPTED MANUSCRIPT

20

National Comprehensive Cancer Network. Practice guidelines in oncology. Available at:

Palliative care. http://www.nccn.org/professionals/physicians_gls/PDP/palliative.pdf. Accessed

21

RI PT

November 4, 2014. Bruera E, Pereira J, Watanabe S, et al. Opioid rotation in patients with cancer pain. A

retrospective comparison of dose ratios between methadone, hydromorphone, and morphine.

22

SC

J.Cancer 1996;78:852-857.

Workgroup on Hypoglycemia, American Diabetes Association. Defining and reporting

M AN U

hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 2005;28:1245-1249. 23

Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration

rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group? Ann Intern Med 1999; 130: 461-470.

Flory JH, Aleman JO, Furst J, Seley JJ. Basal insulin use in the non-critical care setting: is

TE D

24

fasting hypoglycemia inevitable or preventable? J Diabetes Sci Technol 2014;8:427-428. Chariot J, Appia F, Vaille C, Rozé C. Etorphine inhibition of pancreatic exocrine secretion in

EP

25

rats: comparison with methadone. Eur J Pharmacol 1986;121:73-81. Aloisi AM, Buonocore M, Merlo L, et al. Chronic pain therapy and hypothalamic-pituitary-

AC C

26

adrenal axis impairment. Psychoneuroendocrinology 2011;36:1032-1039. 27

Brase DA, Singha AK, Estrada U, Lux F, Dewey WL. Hypoglycemia induced by intrathecal

opioids in mice: stereospecificity, drug specificity and effect of fasting. J Pharmacol Exp Ther 1990;253:899-904.

24

ACCEPTED MANUSCRIPT

28

Gorman AL, Elliott KJ, Inturrisi CE. The d- and l-isomers of methadone bind to the non-

competitive site on the N-methyl-D-aspartate (NMDA) receptor in rat forebrain and spinal cord.

29

RI PT

Neurosci Lett 1997; 223: 5–8. Codd EE, Shank RP, Schupsky JJ, Raffa RB. Serotonin and norepinephrine uptake inhibiting

activity of centrally acting analgesics: structural determinants and role in antinociception. J

30

SC

Pharmacol Exp Ther 1995;274:1263-1270.

Cryer PE. Hypoglycemia, functional brain failure, and brain death. J Clin Invest

AC C

EP

TE D

M AN U

2007;117:868-870.

25

ACCEPTED MANUSCRIPT

Methadone Oral <= 15 mg

●

Methadone Oral 15−40 mg Methadone Oral 40−80 mg

●

Methadone Oral > 80 mg ●

Methadone IV 15−40 mg*

M AN U

●

Methadone IV 40−80 mg*

●

Methadone IV > 80 mg* Methadone PCA Other Opioid Oral <= 40 mg*

● ●

TE D

●

Other Opioid Oral > 40 mg*

●

Other Opioid IV <= 15 mg*

EP

●

AC C

Other Opioid IV 40−80 mg*

SC

●

Methadone IV <= 15 mg*

Other Opioid IV 15−40 mg*

RI PT

●

Other Opioid IV > 80 mg*

Other Opioid PCA Transdermal Opioid

●

● ● ●

●

0

1

2

3

Odds Ratio

4

5

ACCEPTED MANUSCRIPT

Methadone Oral <= 15 mg

●

Methadone Oral 15−40 mg Methadone Oral 40−80 mg

● ●

Methadone IV <= 15 mg*

●

Methadone IV 15−40 mg* ●

Methadone IV > 80 mg*

●

Methadone PCA

Other Opioid IV 15−40 mg*

● ● ● ● ●

AC C

Other Opioid IV 40−80 mg*

TE D

Other Opioid IV <= 15 mg*

●

EP

Other Opioid Oral > 40 mg*

M AN U

●

Methadone IV 40−80 mg*

Other Opioid Oral <= 40 mg*

SC

Methadone Oral > 80 mg

RI PT

●

Other Opioid IV > 80 mg*

●

Other Opioid PCA

●

Transdermal Opioid

●

−10

−5

0

5

10

Effect on Minimum Blood Sugar (mg/dl)

15

ACCEPTED MANUSCRIPT

EP

115

TE D

High Dose Exposure

110

●

●

AC C

105

●

100

●

●

90

95

●

Pre− Exposure

Day 0

Day 1

Day 2

Day 3+

Post− Exposure

RI PT

0.10

SC

Post− Exposure

Day 3+

Day 2

Day 3+

●

Day 0

Day 1

Post− Exposure

●

High Dose Exposure 0.15

Day 2

●

0.10

Day 1

Pre− Exposure

● ●

●

● ●

0.05

Day 0

●

●

0.00

Pre− Exposure

●

M AN U

95

100

●

Proportion of Days With Hypoglycemia

105

●

0.05

●

0.00

Proportion of Days With Hypoglycemia

115 110

●

●

90

Average Minimum Daily Glucose

●

Average Minimum Daily Glucose

Low Dose Exposure

0.15

Low Dose Exposure

●

Pre− Exposure

● ●

Day 0

Day 1

Day 2

Day 3+

Post− Exposure

ACCEPTED MANUSCRIPT

AC C

EP

TE D

M AN U

SC

RI PT

Supplementary Data: Primary analysis repeated after restriction to population of patients with no missing data. Panel 1 is odds ratio for hypoglycemia; panel 2 is change in lowest recorded serum glucose in mg/dl.

ACCEPTED MANUSCRIPT

Methadone Oral 0−15 mg

●

Methadone Oral 15−40 mg

RI PT

●

Methadone Oral 40−80 mg

●

●

Methadone IV 15−40 mg*

●

M AN U

Methadone IV 0−15 mg*

Methadone IV 40−80 mg* Methadone IV > 80 mg* Methadone PCA Other Opioid Oral 0−40 mg* ●

●

EP

●

AC C

Other Opioid IV 40−80 mg*

●

●

Other Opioid IV 0−15 mg* Other Opioid IV 15−40 mg*

●

TE D

Other Opioid Oral > 40 mg*

●

SC

Methadone Oral > 80 mg

●

Other Opioid IV > 80 mg*

●

Other Opioid PCA Transdermal Opioid

●

● ●

0

1

2

3

Odds Ratio

4

5

ACCEPTED MANUSCRIPT

Methadone Oral 0−15 mg

●

Methadone Oral 15−40 mg Methadone Oral 40−80 mg Methadone Oral > 80 mg

RI PT

● ● ●

Methadone IV 0−15 mg*

SC

●

Methadone IV 15−40 mg*

M AN U

●

Methadone IV 40−80 mg*

●

Methadone IV > 80 mg*

Other Opioid Oral > 40 mg* Other Opioid IV 0−15 mg* Other Opioid IV 15−40 mg*

● ● ●

● ●

AC C

Other Opioid IV 40−80 mg*

TE D

Other Opioid Oral 0−40 mg*

●

EP

Methadone PCA

●

Other Opioid IV > 80 mg*

●

Other Opioid PCA

●

Transdermal Opioid

●

−10

−5

0

5

10

Effect on Minimum Blood Sugar (mg/dl)

15